Review



oxiselecttm bpde dna adduct elisa kit  (Cell Biolabs Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Cell Biolabs Inc oxiselecttm bpde dna adduct elisa kit
    Oxiselecttm Bpde Dna Adduct Elisa Kit, supplied by Cell Biolabs Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bpde+dna+adduct+elisa+kit/adduct+competitive+elisa+hne+kit+oxiselect/pmc12446216-86-12-19
    Average 86 stars, based on 1 article reviews
    oxiselecttm bpde dna adduct elisa kit - by Bioz Stars, 2026-10
    86/100 stars

    Images

    Related Articles

    Enzyme-linked Immunosorbent Assay:

    Article Title: A Unique Chimeric RNA: ERCC1‐iASPP Drives Benzo[a]pyrene‐Induced Lung Carcinogenesis via Dual Coding and Non‐Coding Mechanisms
    Article Snippet: Genomic DNA was extracted from human lung cancer tissues using the Universal Genomic DNA Extraction Kit (Takara, Japan). .. BPDE‐DNA adduct levels were quantified with the BPDE‐DNA Adduct ELISA Kit (Cell Biolabs, USA) according to the manufacturer's protocol. ..

    Article Title: A Unique Chimeric RNA: ERCC1-iASPP Drives Benzo[a]pyrene-Induced Lung Carcinogenesis via Dual Coding and Non-Coding Mechanisms.
    Article Snippet: Determination of BPDE-DNA Adducts in Lung Cancer Tissues: Genomic DNA was extracted from human lung cancer tissues using the Universal Genomic DNA Extraction Kit (Takara, Japan). .. BPDE-DNA adduct levels were quantified with the BPDE-DNA Adduct ELISA Kit (Cell Biolabs, USA) according to the manufacturer’s protocol. ..



    Similar Products

    oxiselecttm bpde dna adduct elisa kit  (Cell Biolabs Inc)
    86
    Cell Biolabs Inc oxiselecttm bpde dna adduct elisa kit
    Oxiselecttm Bpde Dna Adduct Elisa Kit, supplied by Cell Biolabs Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bpde+dna+adduct+elisa+kit/adduct+competitive+elisa+hne+kit+oxiselect/pmc12446216-86-12-19
    Average 86 stars, based on 1 article reviews
    oxiselecttm bpde dna adduct elisa kit - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    bpde dna adduct elisa kit  (Cell Biolabs Inc)
    86
    Cell Biolabs Inc bpde dna adduct elisa kit
    A novel oncogenic chimeric RNA ERCC1‐iASPP was found in lung cancer. A) Chimeric RNA ERCC1‐iASPP formation, schematic diagram of specific primer design, and peak melting curve. B) Agarose gel electrophoresis and Sanger sequencing determined the existence of ERCC1‐iASPP . C) 3'RACE, 5'RACE determined the full‐length sequence of ERCC1‐iASPP . D) mRNA expression of ERCC1‐iASPP in various cell lines, in which transformed malignant and lung cancer cells showed high expression levels. E) Primer design, PCR identification, and analysis of ERCC1 , iASPP intergenic region. F) miEAA analysis of ERCC1‐iASPP disease‐associated cloud plots. G) ERCC1‐iASPP expression levels in lung cancer tissues and their adjacent nonmalignant tissues (n = 60), comparing the differential expression of ERCC1‐iASPP in cancer tissues of 29 smokers and 31 non‐smokers, and categorizing lung cancer cases into non‐smokers (n = 31), light smokers (n = 7), moderate smokers (n = 14), and heavy smokers (n = 8) according to the number of pack‐years of smoking, and comparing them with the non‐smokers. The smoking group was compared to analyze changes in ERCC1‐iASPP expression. Pack‐years = (packs smoked per day) × (years as a smoker). H) Correlation <t>between</t> <t>BPDE‐DNA</t> adduct concentration (ng/mL) and ERCC1‐iASPP mRNA expression in tissues of smokers (n = 32). * P < 0.05, ** P < 0.01 and *** P < 0.001. ns: the difference is not statistically significant. Data represent the mean ± SD. D: n = 3, Student's t ‐test; G: Paired Samples t ‐test and Kruskal‐Wallis test; H: Pearson Correlation Test.
    Bpde Dna Adduct Elisa Kit, supplied by Cell Biolabs Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bpde+dna+adduct+elisa+kit/adduct+competitive+elisa+hne+kit+oxiselect/pmc12884745-213-7-11
    Average 86 stars, based on 1 article reviews
    bpde dna adduct elisa kit - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    bpde-dna adduct elisa kit  (Cell Biolabs Inc)
    90
    Cell Biolabs Inc bpde-dna adduct elisa kit
    A novel oncogenic chimeric RNA ERCC1‐iASPP was found in lung cancer. A) Chimeric RNA ERCC1‐iASPP formation, schematic diagram of specific primer design, and peak melting curve. B) Agarose gel electrophoresis and Sanger sequencing determined the existence of ERCC1‐iASPP . C) 3'RACE, 5'RACE determined the full‐length sequence of ERCC1‐iASPP . D) mRNA expression of ERCC1‐iASPP in various cell lines, in which transformed malignant and lung cancer cells showed high expression levels. E) Primer design, PCR identification, and analysis of ERCC1 , iASPP intergenic region. F) miEAA analysis of ERCC1‐iASPP disease‐associated cloud plots. G) ERCC1‐iASPP expression levels in lung cancer tissues and their adjacent nonmalignant tissues (n = 60), comparing the differential expression of ERCC1‐iASPP in cancer tissues of 29 smokers and 31 non‐smokers, and categorizing lung cancer cases into non‐smokers (n = 31), light smokers (n = 7), moderate smokers (n = 14), and heavy smokers (n = 8) according to the number of pack‐years of smoking, and comparing them with the non‐smokers. The smoking group was compared to analyze changes in ERCC1‐iASPP expression. Pack‐years = (packs smoked per day) × (years as a smoker). H) Correlation <t>between</t> <t>BPDE‐DNA</t> adduct concentration (ng/mL) and ERCC1‐iASPP mRNA expression in tissues of smokers (n = 32). * P < 0.05, ** P < 0.01 and *** P < 0.001. ns: the difference is not statistically significant. Data represent the mean ± SD. D: n = 3, Student's t ‐test; G: Paired Samples t ‐test and Kruskal‐Wallis test; H: Pearson Correlation Test.
    Bpde Dna Adduct Elisa Kit, supplied by Cell Biolabs Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bpde+dna+adduct+elisa+kit/bpde+dna+adduct+elisa+kit/pm40259856-111-7-11
    Average 90 stars, based on 1 article reviews
    bpde-dna adduct elisa kit - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    benzo(a)pyrene diolepoxide (bpde) dna adducts elisa kit  (Cell Biolabs Inc)
    90
    Cell Biolabs Inc benzo(a)pyrene diolepoxide (bpde) dna adducts elisa kit
    A novel oncogenic chimeric RNA ERCC1‐iASPP was found in lung cancer. A) Chimeric RNA ERCC1‐iASPP formation, schematic diagram of specific primer design, and peak melting curve. B) Agarose gel electrophoresis and Sanger sequencing determined the existence of ERCC1‐iASPP . C) 3'RACE, 5'RACE determined the full‐length sequence of ERCC1‐iASPP . D) mRNA expression of ERCC1‐iASPP in various cell lines, in which transformed malignant and lung cancer cells showed high expression levels. E) Primer design, PCR identification, and analysis of ERCC1 , iASPP intergenic region. F) miEAA analysis of ERCC1‐iASPP disease‐associated cloud plots. G) ERCC1‐iASPP expression levels in lung cancer tissues and their adjacent nonmalignant tissues (n = 60), comparing the differential expression of ERCC1‐iASPP in cancer tissues of 29 smokers and 31 non‐smokers, and categorizing lung cancer cases into non‐smokers (n = 31), light smokers (n = 7), moderate smokers (n = 14), and heavy smokers (n = 8) according to the number of pack‐years of smoking, and comparing them with the non‐smokers. The smoking group was compared to analyze changes in ERCC1‐iASPP expression. Pack‐years = (packs smoked per day) × (years as a smoker). H) Correlation <t>between</t> <t>BPDE‐DNA</t> adduct concentration (ng/mL) and ERCC1‐iASPP mRNA expression in tissues of smokers (n = 32). * P < 0.05, ** P < 0.01 and *** P < 0.001. ns: the difference is not statistically significant. Data represent the mean ± SD. D: n = 3, Student's t ‐test; G: Paired Samples t ‐test and Kruskal‐Wallis test; H: Pearson Correlation Test.
    Benzo(a)pyrene Diolepoxide (Bpde) Dna Adducts Elisa Kit, supplied by Cell Biolabs Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bpde+dna+adduct+elisa+kit/bpde+dna+adduct+elisa+kit/pm39043924-161-16-24
    Average 90 stars, based on 1 article reviews
    benzo(a)pyrene diolepoxide (bpde) dna adducts elisa kit - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    bpde-dna adduct elisa kit sta–357  (Cell Biolabs Inc)
    90
    Cell Biolabs Inc bpde-dna adduct elisa kit sta–357
    A novel oncogenic chimeric RNA ERCC1‐iASPP was found in lung cancer. A) Chimeric RNA ERCC1‐iASPP formation, schematic diagram of specific primer design, and peak melting curve. B) Agarose gel electrophoresis and Sanger sequencing determined the existence of ERCC1‐iASPP . C) 3'RACE, 5'RACE determined the full‐length sequence of ERCC1‐iASPP . D) mRNA expression of ERCC1‐iASPP in various cell lines, in which transformed malignant and lung cancer cells showed high expression levels. E) Primer design, PCR identification, and analysis of ERCC1 , iASPP intergenic region. F) miEAA analysis of ERCC1‐iASPP disease‐associated cloud plots. G) ERCC1‐iASPP expression levels in lung cancer tissues and their adjacent nonmalignant tissues (n = 60), comparing the differential expression of ERCC1‐iASPP in cancer tissues of 29 smokers and 31 non‐smokers, and categorizing lung cancer cases into non‐smokers (n = 31), light smokers (n = 7), moderate smokers (n = 14), and heavy smokers (n = 8) according to the number of pack‐years of smoking, and comparing them with the non‐smokers. The smoking group was compared to analyze changes in ERCC1‐iASPP expression. Pack‐years = (packs smoked per day) × (years as a smoker). H) Correlation <t>between</t> <t>BPDE‐DNA</t> adduct concentration (ng/mL) and ERCC1‐iASPP mRNA expression in tissues of smokers (n = 32). * P < 0.05, ** P < 0.01 and *** P < 0.001. ns: the difference is not statistically significant. Data represent the mean ± SD. D: n = 3, Student's t ‐test; G: Paired Samples t ‐test and Kruskal‐Wallis test; H: Pearson Correlation Test.
    Bpde Dna Adduct Elisa Kit Sta–357, supplied by Cell Biolabs Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bpde+dna+adduct+elisa+kit/bpde+dna+adduct+elisa+kit/pm38438030-87-8-13
    Average 90 stars, based on 1 article reviews
    bpde-dna adduct elisa kit sta–357 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    oxiselect bpde dna adduct elisa kit  (Cell Biolabs Inc)
    90
    Cell Biolabs Inc oxiselect bpde dna adduct elisa kit
    A novel oncogenic chimeric RNA ERCC1‐iASPP was found in lung cancer. A) Chimeric RNA ERCC1‐iASPP formation, schematic diagram of specific primer design, and peak melting curve. B) Agarose gel electrophoresis and Sanger sequencing determined the existence of ERCC1‐iASPP . C) 3'RACE, 5'RACE determined the full‐length sequence of ERCC1‐iASPP . D) mRNA expression of ERCC1‐iASPP in various cell lines, in which transformed malignant and lung cancer cells showed high expression levels. E) Primer design, PCR identification, and analysis of ERCC1 , iASPP intergenic region. F) miEAA analysis of ERCC1‐iASPP disease‐associated cloud plots. G) ERCC1‐iASPP expression levels in lung cancer tissues and their adjacent nonmalignant tissues (n = 60), comparing the differential expression of ERCC1‐iASPP in cancer tissues of 29 smokers and 31 non‐smokers, and categorizing lung cancer cases into non‐smokers (n = 31), light smokers (n = 7), moderate smokers (n = 14), and heavy smokers (n = 8) according to the number of pack‐years of smoking, and comparing them with the non‐smokers. The smoking group was compared to analyze changes in ERCC1‐iASPP expression. Pack‐years = (packs smoked per day) × (years as a smoker). H) Correlation <t>between</t> <t>BPDE‐DNA</t> adduct concentration (ng/mL) and ERCC1‐iASPP mRNA expression in tissues of smokers (n = 32). * P < 0.05, ** P < 0.01 and *** P < 0.001. ns: the difference is not statistically significant. Data represent the mean ± SD. D: n = 3, Student's t ‐test; G: Paired Samples t ‐test and Kruskal‐Wallis test; H: Pearson Correlation Test.
    Oxiselect Bpde Dna Adduct Elisa Kit, supplied by Cell Biolabs Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bpde+dna+adduct+elisa+kit/bpde+dna+adduct+elisa+kit/pm38310363-134-1-7
    Average 90 stars, based on 1 article reviews
    oxiselect bpde dna adduct elisa kit - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    A novel oncogenic chimeric RNA ERCC1‐iASPP was found in lung cancer. A) Chimeric RNA ERCC1‐iASPP formation, schematic diagram of specific primer design, and peak melting curve. B) Agarose gel electrophoresis and Sanger sequencing determined the existence of ERCC1‐iASPP . C) 3'RACE, 5'RACE determined the full‐length sequence of ERCC1‐iASPP . D) mRNA expression of ERCC1‐iASPP in various cell lines, in which transformed malignant and lung cancer cells showed high expression levels. E) Primer design, PCR identification, and analysis of ERCC1 , iASPP intergenic region. F) miEAA analysis of ERCC1‐iASPP disease‐associated cloud plots. G) ERCC1‐iASPP expression levels in lung cancer tissues and their adjacent nonmalignant tissues (n = 60), comparing the differential expression of ERCC1‐iASPP in cancer tissues of 29 smokers and 31 non‐smokers, and categorizing lung cancer cases into non‐smokers (n = 31), light smokers (n = 7), moderate smokers (n = 14), and heavy smokers (n = 8) according to the number of pack‐years of smoking, and comparing them with the non‐smokers. The smoking group was compared to analyze changes in ERCC1‐iASPP expression. Pack‐years = (packs smoked per day) × (years as a smoker). H) Correlation between BPDE‐DNA adduct concentration (ng/mL) and ERCC1‐iASPP mRNA expression in tissues of smokers (n = 32). * P < 0.05, ** P < 0.01 and *** P < 0.001. ns: the difference is not statistically significant. Data represent the mean ± SD. D: n = 3, Student's t ‐test; G: Paired Samples t ‐test and Kruskal‐Wallis test; H: Pearson Correlation Test.

    Journal: Advanced Science

    Article Title: A Unique Chimeric RNA: ERCC1‐iASPP Drives Benzo[a]pyrene‐Induced Lung Carcinogenesis via Dual Coding and Non‐Coding Mechanisms

    doi: 10.1002/advs.202507217

    Figure Lengend Snippet: A novel oncogenic chimeric RNA ERCC1‐iASPP was found in lung cancer. A) Chimeric RNA ERCC1‐iASPP formation, schematic diagram of specific primer design, and peak melting curve. B) Agarose gel electrophoresis and Sanger sequencing determined the existence of ERCC1‐iASPP . C) 3'RACE, 5'RACE determined the full‐length sequence of ERCC1‐iASPP . D) mRNA expression of ERCC1‐iASPP in various cell lines, in which transformed malignant and lung cancer cells showed high expression levels. E) Primer design, PCR identification, and analysis of ERCC1 , iASPP intergenic region. F) miEAA analysis of ERCC1‐iASPP disease‐associated cloud plots. G) ERCC1‐iASPP expression levels in lung cancer tissues and their adjacent nonmalignant tissues (n = 60), comparing the differential expression of ERCC1‐iASPP in cancer tissues of 29 smokers and 31 non‐smokers, and categorizing lung cancer cases into non‐smokers (n = 31), light smokers (n = 7), moderate smokers (n = 14), and heavy smokers (n = 8) according to the number of pack‐years of smoking, and comparing them with the non‐smokers. The smoking group was compared to analyze changes in ERCC1‐iASPP expression. Pack‐years = (packs smoked per day) × (years as a smoker). H) Correlation between BPDE‐DNA adduct concentration (ng/mL) and ERCC1‐iASPP mRNA expression in tissues of smokers (n = 32). * P < 0.05, ** P < 0.01 and *** P < 0.001. ns: the difference is not statistically significant. Data represent the mean ± SD. D: n = 3, Student's t ‐test; G: Paired Samples t ‐test and Kruskal‐Wallis test; H: Pearson Correlation Test.

    Article Snippet: BPDE‐DNA adduct levels were quantified with the BPDE‐DNA Adduct ELISA Kit (Cell Biolabs, USA) according to the manufacturer's protocol.

    Techniques: Agarose Gel Electrophoresis, Sequencing, Expressing, Transformation Assay, Quantitative Proteomics, Concentration Assay